The U.S. FDA approved Novo Nordisk A/S’ diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co.’s Trulicity.
Indivior’s experimental drug to help fight America’s growing opioid addiction crisis was approved by the U.S. Food and Drug Administration, boosting the company’s sales prospects as competitors threaten revenues from an older product.
Use of Sanofi’s dengue vaccine, the world’s first approved shot against the mosquito-borne virus, is to be strictly limited due to evidence it can worsen the disease in people who have not previously been exposed to the infection.
Germany’s Merck KGaA suffered a setback in the development of the company’s key cancer immunotherapy Bavencio, which failed in a trial to prolong lives in gastric cancer patients when compared with standard chemotherapy.
Biogen Inc. licensed Alkermes Plc’s multiple sclerosis drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug Tecfidera.
Bayer is seeking to defend its pharmaceuticals business that will be diluted in importance by the takeover of Monsanto.
Johnson & Johnson’s blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with the standard therapy alone in patients not previously treated for the blood cancer, according to released data.
Acorda Therapeutics Inc. said the company would stop developing its Parkinson’s disease drug tozadenant less than a week after reporting deaths in key studies testing the treatment.
Roche shares were lifted by two clinical trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker is counting on to offset shrinking revenue from older medicines.
Acorda Therapeutics Inc. said five people died in clinical trials for the company’s Parkinson’s disease drug, the latest in a series of setbacks for the drugmaker.